Switch theme
Sign up to access all valuation multiples
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
2013
244
LTM Revenue $64.0M
LTM EBITDA -$173M
-$181M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alector has a last 12-month revenue (LTM) of $64.0M and a last 12-month EBITDA of -$173M.
In the most recent fiscal year, Alector achieved revenue of $101M and an EBITDA of -$136M.
Alector expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alector valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $64.0M | XXX | $101M | XXX | XXX | XXX |
| Gross Profit | $35.5M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 56% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$173M | XXX | -$136M | XXX | XXX | XXX |
| EBITDA Margin | -270% | XXX | -135% | XXX | XXX | XXX |
| EBIT | -$169M | XXX | -$145M | XXX | XXX | XXX |
| EBIT Margin | -264% | XXX | -144% | XXX | XXX | XXX |
| Net Profit | -$147M | XXX | -$119M | XXX | XXX | XXX |
| Net Margin | -230% | XXX | -118% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Alector's stock price is $1.
Alector has current market cap of $133M, and EV of -$181M.
See Alector trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$181M | $133M | XXX | XXX | XXX | XXX | $-1.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Alector has market cap of $133M and EV of -$181M.
Alector's trades at -1.8x EV/Revenue multiple, and 1.3x EV/EBITDA.
Equity research analysts estimate Alector's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alector has a P/E ratio of -0.9x.
See valuation multiples for Alector and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $133M | XXX | $133M | XXX | XXX | XXX |
| EV (current) | -$181M | XXX | -$181M | XXX | XXX | XXX |
| EV/Revenue | -2.8x | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBITDA | 1.0x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBIT | 1.1x | XXX | 1.2x | XXX | XXX | XXX |
| EV/Gross Profit | -5.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -1.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAlector's last 12 month revenue growth is -56%
Alector's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $1.0M for the same period.
Alector's rule of 40 is -203% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alector's rule of X is -410% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Alector and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -56% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -270% | XXX | -135% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 24% | XXX | XXX | XXX |
| Rule of 40 | -203% | XXX | -191% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -410% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 185% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 244% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alector acquired XXX companies to date.
Last acquisition by Alector was XXXXXXXX, XXXXX XXXXX XXXXXX . Alector acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Alector founded? | Alector was founded in 2013. |
| Where is Alector headquartered? | Alector is headquartered in United States of America. |
| How many employees does Alector have? | As of today, Alector has 244 employees. |
| Who is the CEO of Alector? | Alector's CEO is Dr. Arnon Rosenthal, PhD. |
| Is Alector publicy listed? | Yes, Alector is a public company listed on NAS. |
| What is the stock symbol of Alector? | Alector trades under ALEC ticker. |
| When did Alector go public? | Alector went public in 2019. |
| Who are competitors of Alector? | Similar companies to Alector include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Alector? | Alector's current market cap is $133M |
| What is the current revenue of Alector? | Alector's last 12 months revenue is $64.0M. |
| What is the current revenue growth of Alector? | Alector revenue growth (NTM/LTM) is -56%. |
| What is the current EV/Revenue multiple of Alector? | Current revenue multiple of Alector is -2.8x. |
| Is Alector profitable? | Yes, Alector is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alector? | Alector's last 12 months EBITDA is -$173M. |
| What is Alector's EBITDA margin? | Alector's last 12 months EBITDA margin is -270%. |
| What is the current EV/EBITDA multiple of Alector? | Current EBITDA multiple of Alector is 1.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
